Ethris GmbH is a Germany-based biotechnology company developing RNA-based therapeutics and vaccines, with a core focus on the design, chemical modification, and formulation of messenger RNA (mRNA) and other nucleic acids. Headquartered in Planegg near Munich, the company advances drug candidates for respiratory and other diseases, emphasizing clinically viable delivery and dosing strategies.
Ethris’ work spans sequence engineering, analytical characterization, and drug product development for nucleic acid medicines. The company develops non-viral delivery systems—such as lipid nanoparticle (LNP) formulations and inhaled/aerosolizable dosage forms—to enable targeted, local or systemic administration. Ethris collaborates with pharmaceutical manufacturers, materials suppliers, and CDMOs to translate nucleic acid technologies from preclinical research into early clinical development, contributing know-how in formulation science, stability, and scalable process development relevant to the chemical and life-science supply chain.
